Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Receivables (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Change in Receivables for 13 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 296.57% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $756000.0 through Dec 2025, down 40.89% year-over-year, with the annual reading at $756000.0 for FY2025, 40.89% down from the prior year.
  • Change in Receivables for Q4 2025 was $1.3 million at Niagen Bioscience, up from -$1.2 million in the prior quarter.
  • The five-year high for Change in Receivables was $3.8 million in Q4 2022, with the low at -$2.7 million in Q2 2023.
  • Average Change in Receivables over 5 years is $283850.0, with a median of $326000.0 recorded in 2021.
  • Peak annual rise in Change in Receivables hit 2802.31% in 2022, while the deepest fall reached 251.76% in 2022.
  • Over 5 years, Change in Receivables stood at $130000.0 in 2021, then skyrocketed by 2802.31% to $3.8 million in 2022, then crashed by 109.22% to -$348000.0 in 2023, then plummeted by 84.48% to -$642000.0 in 2024, then soared by 296.57% to $1.3 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $1.3 million, -$1.2 million, and $2.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.